Animal Research Context: Scaling from Rodents Preclinical studies with Dihexa and angiotensin IV analogues employed doses that ranged considerably depending on species, route, and outcome measured: Intravenous (IV) Administration Animal studies using intravenous dosing (which bypasses absorption barriers and achieves near-complete bioavailability) reported cognitive and neuroprotective effects at: 0.1 to 2.0 mg/kg in rodent studies (McCoy et al., 2013) Doses at the higher end of this range (12 mg/kg IV) produced robust behavioral effects For a 70 kg human, equivalent to 70140 mg total IV dose (crude extrapolation) However, direct extrapolation from rodents to humans is unreliable due to differences in metabolism, brain penetration, and receptor sensitivity Intraperitoneal (IP) Administration IP dosing (injection into the abdominal cavity, with slower absorption than IV) showed effects at: Up to 10 mg/kg in some studies Lower bioavailability than IV, requiring higher nominal doses for similar effects This route is not practical for human use Why Rodent Dosing Doesn't Directly Translate Rodent pharmacokinetics differ substantially from humans

Contact us at 864-884-6202 to schedule your consultation at Botox Boutique today and say hello to a more energized, vibrant you!
For example, a group of 58 women with cervical dysplasia seen on colposcopy (CIN1), ages 18 to 58, were enrolled in a randomized, double-blind, placebo controlled study, and divided into two groups
In an adult with pattern hair loss or diffuse thinning and no known copper allergy, what is the recommended firstline topical peptide (copperpeptide, GHKCu) regimen?